• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in .对获得性广谱β-内酰胺酶对单独或联合使用β-内酰胺酶抑制剂阿维巴坦和替加环素的口服青霉素类/碳青霉烯类（替比培南、舒巴坦、法罗培南）敏感性的影响。
Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0054723. doi: 10.1128/aac.00547-23. Epub 2023 Sep 5.
2
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.获得性广谱β-内酰胺酶对大肠埃希菌和铜绿假单胞菌中新型β-内酰胺类（氨曲南、头孢吡肟、美罗培南和亚胺培南）和新型β-内酰胺酶抑制剂组合药物敏感性的影响。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. doi: 10.1128/aac.00339-23. Epub 2023 May 31.
3
potency of xeruborbactam in combination with multiple β-lactam antibiotics in comparison with other β-lactam/β-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum β-lactamase-producing .比较 X 型头孢洛巴坦与其他β-内酰胺/β-内酰胺酶抑制剂（BLI）组合对碳青霉烯类耐药和产超广谱β-内酰胺酶的抗菌活性。
Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0044023. doi: 10.1128/aac.00440-23. Epub 2023 Oct 6.
4
Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases.VNRX-5236 的微生物学特征，一种广谱β-内酰胺酶抑制剂，用于挽救口服生物利用度头孢菌素头孢布烯，作为一种节约碳青霉烯类药物的药物，针对表达扩展谱β-内酰胺酶和丝氨酸碳青霉烯酶的菌株。
Antimicrob Agents Chemother. 2021 Jul 16;65(8):e0055221. doi: 10.1128/AAC.00552-21.
5
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China.新型β-内酰胺酶抑制剂他尼硼巴坦（VNRX-5133）联合头孢吡肟或美罗培南对来自中国的多重耐药革兰氏阴性菌分离株的体外活性。
J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. doi: 10.1093/jac/dkaa053.
6
Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.舒巴坦钠：一种用于治疗多重耐药菌引起的尿路感染的静脉注射和口服青霉素类药物。
Drugs. 2022 Apr;82(5):533-557. doi: 10.1007/s40265-022-01688-1. Epub 2022 Mar 16.
7
Strongly Bactericidal All-Oral β-Lactam Combinations for the Treatment of Mycobacterium abscessus Lung Disease.强烈杀菌的全口服β-内酰胺类药物联合治疗用于治疗脓肿分枝杆菌肺病。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0079022. doi: 10.1128/aac.00790-22. Epub 2022 Sep 1.
8
In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.新型β-内酰胺酶抑制剂他尼硼巴坦与头孢吡肟或美罗培南对肺炎克雷伯菌的体外比较活性以及头孢吡肟对产金属β-内酰胺酶的铜绿假单胞菌临床分离株的体外比较活性。
Int J Antimicrob Agents. 2021 Nov;58(5):106440. doi: 10.1016/j.ijantimicag.2021.106440. Epub 2021 Sep 20.
9
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria.β-内酰胺/替加环素（VNRX-5133）联合用药对碳青霉烯类耐药革兰氏阴性菌的活性。
J Antimicrob Chemother. 2021 Jan 1;76(1):160-170. doi: 10.1093/jac/dkaa391.
10
Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of strains producing broad-spectrum β-lactamases.产广谱β-内酰胺酶菌株中青霉素结合蛋白 3 修饰对头孢他啶-阿维巴坦、亚胺培南-雷巴坦、美罗培南-沃巴坦、氨曲南-阿维巴坦、头孢吡肟-他唑巴坦和头孢地尔的敏感性的影响。
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0154823. doi: 10.1128/aac.01548-23. Epub 2024 Feb 28.

引用本文的文献

1
Pharmacokinetics/Pharmacodynamics-Based Repositioning of Cefmetazole and Flomoxef in Extended-Spectrum β-Lactamase-Producing Enterobacterales Treatment: An Injectable Carbapenem-Sparing and Outpatient Strategy.基于药代动力学/药效学的头孢美唑和氟氧头孢在产超广谱β-内酰胺酶肠杆菌科细菌治疗中的重新定位：一种可替代注射用碳青霉烯类药物的门诊治疗策略
Antibiotics (Basel). 2025 Jul 23;14(8):737. doi: 10.3390/antibiotics14080737.
2
Activity of novel ceftibuten-avibactam, ceftazidime-avibactam, and comparators against a challenge set of from outpatient centers and nursing homes across the United States (2022-2024).新型头孢布烯-阿维巴坦、头孢他啶-阿维巴坦及对照药物对来自美国各地门诊中心和疗养院的一组受试菌株的活性（2022 - 2024年）
Antimicrob Agents Chemother. 2025 May 7;69(5):e0186724. doi: 10.1128/aac.01867-24. Epub 2025 Apr 3.
3
Spectrum of cefepime-taniborbactam coverage against 190 β-lactamases defined in engineered isogenic strains.头孢吡肟-他尼硼巴坦对工程化同基因菌株中定义的190种β-内酰胺酶的覆盖谱。
Antimicrob Agents Chemother. 2025 May 7;69(5):e0169924. doi: 10.1128/aac.01699-24. Epub 2025 Apr 1.
4
The interaction of the azetidine thiazole side chain with the active site loop (ASL) 3 drives the evolution of IMP metallo-β-lactamase against tebipenem.氮杂环丁烷噻唑侧链与活性位点环（ASL）3 的相互作用推动 IMP 金属-β-内酰胺酶对抗替比培南的进化。
Antimicrob Agents Chemother. 2024 Aug 7;68(8):e0068724. doi: 10.1128/aac.00687-24. Epub 2024 Jul 18.

本文引用的文献

1
Impact of Acquired Broad Spectrum β-Lactamases on Susceptibility to Novel Combinations Made of β-Lactams (Aztreonam, Cefepime, Meropenem, and Imipenem) and Novel β-Lactamase Inhibitors in Escherichia coli and Pseudomonas aeruginosa.获得性广谱β-内酰胺酶对大肠埃希菌和铜绿假单胞菌中新型β-内酰胺类（氨曲南、头孢吡肟、美罗培南和亚胺培南）和新型β-内酰胺酶抑制剂组合药物敏感性的影响。
Antimicrob Agents Chemother. 2023 Jul 18;67(7):e0033923. doi: 10.1128/aac.00339-23. Epub 2023 May 31.
2
NDM-9 resistance to taniborbactam.NDM-9对他尼硼巴坦的耐药性。
Lancet Infect Dis. 2023 Apr;23(4):401-402. doi: 10.1016/S1473-3099(23)00069-5. Epub 2023 Feb 13.
3
In vitro activity of aztreonam in combination with newly developed β-lactamase inhibitors against MDR Enterobacterales and Pseudomonas aeruginosa producing metallo-β-lactamases.氨曲南与新开发的β-内酰胺酶抑制剂联合应用对产金属β-内酰胺酶的多重耐药肠杆菌科细菌和铜绿假单胞菌的体外活性。
J Antimicrob Chemother. 2022 Dec 23;78(1):101-107. doi: 10.1093/jac/dkac360.
4
Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of from a 2018-2020 Global Surveillance Collection.头孢他啶-阿维巴坦对来自 2018-2020 年全球监测收集的多药耐药和产超广谱β-内酰胺酶阳性临床分离株的活性。
Antimicrob Agents Chemother. 2022 Nov 15;66(11):e0093422. doi: 10.1128/aac.00934-22. Epub 2022 Oct 26.
5
Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial.舒巴坦匹酯或环丙沙星治疗女性单纯性尿路感染的随机对照 3 期临床试验
Clin Infect Dis. 2023 Jan 6;76(1):66-77. doi: 10.1093/cid/ciac738.
6
Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.硫酸头孢噻肟治疗包括肾盂肾炎在内的复杂性尿路感染的 3 期随机试验。
Clin Infect Dis. 2023 Jan 6;76(1):78-88. doi: 10.1093/cid/ciac704.
7
Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).美国传染病学会 2022 年关于治疗产超广谱β-内酰胺酶肠杆菌科细菌（ESBL-E）、耐碳青霉烯肠杆菌科细菌（CRE）和治疗困难的耐药铜绿假单胞菌（DTR-P. aeruginosa）的指导意见。
Clin Infect Dis. 2022 Aug 25;75(2):187-212. doi: 10.1093/cid/ciac268.
8
Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.口服氢溴酸替比培南酯治疗复杂性尿路感染
N Engl J Med. 2022 Apr 7;386(14):1327-1338. doi: 10.1056/NEJMoa2105462.
9
Broad-spectrum cyclic boronate β-lactamase inhibitors featuring an intramolecular prodrug for oral bioavailability.具有分子内前药的广谱环状硼酸盐β-内酰胺酶抑制剂，可提高口服生物利用度。
Bioorg Med Chem. 2022 May 15;62:116722. doi: 10.1016/j.bmc.2022.116722. Epub 2022 Mar 23.
10
Oral Antibiotics in Clinical Development for Community-Acquired Urinary Tract Infections.用于社区获得性尿路感染临床开发的口服抗生素
Infect Dis Ther. 2021 Dec;10(4):1815-1835. doi: 10.1007/s40121-021-00509-4. Epub 2021 Aug 6.

对获得性广谱β-内酰胺酶对单独或联合使用β-内酰胺酶抑制剂阿维巴坦和替加环素的口服青霉素类/碳青霉烯类（替比培南、舒巴坦、法罗培南）敏感性的影响。

Impact of acquired broad-spectrum β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) alone or in combination with avibactam and taniborbactam β-lactamase inhibitors in .

机构信息

Emerging Antibiotic Resistance Unit, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg , Fribourg, Switzerland.

Division of Intensive Care Unit, University Hospitals of Geneva , Geneva, Switzerland.

出版信息

Antimicrob Agents Chemother. 2023 Oct 18;67(10):e0054723. doi: 10.1128/aac.00547-23. Epub 2023 Sep 5.

DOI:10.1128/aac.00547-23
PMID:37668385
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10583657/
Abstract

The impact of β-lactamases on susceptibility to oral penems/carbapenems (tebipenem, sulopenem, and faropenem) and other carbapenem molecules was evaluated in , alone and in combination with avibactam or taniborbactam β-lactamase inhibitors. Tebipenem and sulopenem exhibited a similar spectrum of activity compared to the intravenous carbapenems and displayed lower MIC values than ceftibuten-avibactam against producing extended-spectrum β-lactamases or AmpC enzymes. Combined with taniborbactam, tebipenem and sulopenem exhibited low MIC values against almost all tested recombinant , including metallo-β-lactamase producers.

摘要

β-内酰胺酶对口服青霉素类/碳青霉烯类药物（替比培南、司帕培南和法罗培南）和其他碳青霉烯类分子的敏感性的影响，在 单独和与β-内酰胺酶抑制剂阿维巴坦或替加环素联合使用时进行了评估。替比培南和司帕培南与静脉用碳青霉烯类药物具有相似的活性谱，并显示出比头孢布烯-阿维巴坦更低的 MIC 值，对产生超广谱β-内酰胺酶或 AmpC 酶的 。与替加环素联合使用时，替比培南和司帕培南对几乎所有测试的重组 均表现出低 MIC 值，包括金属β-内酰胺酶产生菌。